Índice de hígado graso en mujeres adultas del estado Carabobo, Venezuela. Asociación con síndrome metabólico y riesgo cardiometabólico

Nelina Ruiz-Fernández, Doris Nobrega

Resumen


El índice de hígado graso (IHG) es un buen predictor de la presencia de esteatosis hepática. evaluar el IHG y su asociación con síndrome metabólico (SM), componentes individuales del SM, riesgo cardiometabólico (RCM) y factores de riesgo cardiometabólico no integrados en la definición de SM, en un grupo de mujeres adultas venezolanas. Estudio transversal en 114 mujeres adultas del Estado Carabobo, Venezuela. Se midió presión arterial, indicadores antropométricos y bioquímicos de RCM. Se calculó el IHG y el índice cardiometabólico (ICMet) como indicador de RCM. Se estableció el SM, sus componentes individuales y el riesgo cardiovascular según puntaje de Framingham. El 21,9% de las mujeres presentaron IHG alto (= 60). En comparación con el grupo de mujeres con IHG bajo (< 30), las mujeres con IHG = 60 mostraron valores significativamente superiores de colesterol total (CT), colesterol-LDL, colesterol noHDL, triglicéridos (TGL), ácido úrico, índice CT/colesterol-HDL, índice colesterol-LDL/colesterol-HDL, índice TGL/colesterol-HDL, ICMet, puntaje de Framingham y riesgo cardiovascular. El riesgo de IHG alto se asoció a obesidad central, hipertrigliceridemia, presión arterial elevada, glicemia alterada, RCM elevado y riesgo cardiovascular medio-alto; al ajustar por edad, condición de posmenopausia y concentración de CT, apareció asociado con el SM y se mantuvo su asociación con presión arterial elevada, número de componentes individuales de SM y RCM elevado. Resultados similares se encontraron para IHG intermedio (30-59). El IHG se asoció a SM, elevado RCM y a otros factores de riesgo cardiometabólico. Las mujeres con IHG = 30 deben ser monitoreadas.

Recibido: 11/06/2021
Aprobado: 20/06/2021


Palabras clave


Hígado graso; Síndrome metabólico; Factores de riesgo; Enfermedades cardiovasculares

Texto completo:

PDF

Referencias


European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388-1402.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatolog 2016;64(1):73-84.

Castro L, Silva G. Hígado graso no alcohólico. Rev Med Clin Condes 2015;26(5):600-612.

Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol 2018;68(2):335-352.

Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33(10):1190-200.

Bedogni G, Ballentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006;6:33.

Zhu J, He M, Zhang Y, Li T, Liu Y, Xu Z, et al. Validation of simple indexes

for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. Endocr J 2018;65(3):373-381.

Gaviria G, Uzcátegui L, Gómez R, Uzcátegui E, Baptista T, Martínez D, et al. Frecuencia de hígado graso no alcohólico en pacientes con síndrome metabólico: estudio poblacional en el Municipio Libertador del Estado Mérida. MedULA 2012;21(1):18-25.

Organización Mundial de la Salud. El Estado Físico: Uso e Interpretación de la Antropometría. WHO Technical Report Series, 854. Ginebra: World Health Organization; 1995. (Fecha de acceso: 18 de junio de 2020(. Disponible en: http://apps.who.int/iris/bitstream/handle/10665/42132/WHO_TRS_854_spa.pdf;jsessionid=6FC4A30C4FE2956CF4B11829C1FF3B79?sequence=1.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640-1645.

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289(19):2560-2572.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002;106(25):3143-3421.

Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.Vasc Health Risk Manag 2009;5:757-765.

McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005;96(3):399-404.

Expert Dyslipidemia Panel, Grundy SM. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol 2013;7(6):561-565.

Wakabayashi I, Daimon T. The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta 2015;438:274-278.

Wilson P, D’Agostino R., Levy D, Belanger AM, Silbershatz H, Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837-1847.

American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41 Suppl1:S13-S27.

Arshad T, Golabi P, Paik J, Mishra A, Younossi ZM. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol Commun 2019;3(1):74-83.

Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010;22(1):24-32.

Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS. The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population. Hepatobiliary Pancreat Dis Int 2017;16(2):176-180.

Van den Berg EH, Amini M, Schreuder TC, Dullaart RP, Faber KN, Alizadeh BZ, et al. Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort. PLoS One 2017;12(2):e0171502.

Cheng YL, Wang YJ, Lan KH, Huo TI, Huang YH, Su CW, et al. Fatty liver index and lipid accumulation product can predict metabolic syndrome in subjects without fatty liver disease. Gastroenterol Res Pract 2017;2017:9279836.

Lim S, Taskinen MR, Borén J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes Rev 2019; 20(4):599-611.

Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009;49(5):1537-1544.

Hong H, Hwang S, Ryu J, Yoo H, Seo J, Kim S. The synergistic impact of nonalcoholic fatty liver disease and metabolic syndrome on subclinical aterosclerosis. Clin Endocrinol 2016;84(2):203-209.

Olubamwo O, Virtanen J, Voutilainen A, Kauhanen J, Pihlajamäki J, Tuomainen TP. Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction. Eur J Gastroenterol Hepatol 2018;30(9):1047-1054.

Wu KT, Kuo PL, Su SB, Chen YY, Yeh ML, Huang CI, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol 2016;10(2):420-425.e1.

Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, et al. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2017;27(1):63-69.

Peng K, Mo Z, Tian G. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males. Am J Med Sci 2017;353(3):236-241.

Zelber-Sagi S, Salomone F, Yeshua H, Lotan R, Webb M, Halpern Z, et al. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int 2014;34(6):e128-135.

Hwang IC, Suh SY, Suh AR, Ahn HY. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J Korean Med Sci 2011;26(3):386-391.

Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem 2016;49(7-8):636-642.





Se encuentra actualmente indizada en:
tanaman herbal berkhasiat obat  

Creative Commons License
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.